http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View More Recent Stories
-
Advaxis's Cancer Immunotherapy Featured on CBS News
-
Advaxis Receives Notice of Allowance From U.S. Patent Office for Two Patent Applications With Multiple Claims Covering Its Cancer Immunotherapy ADXS-cHER2
-
Advaxis to Present at BIO International Convention
-
Advaxis Provides Business Update
-
Advaxis Announces Business Update Conference Call
-
Advaxis's ADXS-cHER2 Immunotherapy Continues to Demonstrate Significantly Prolonged Survival in Canine Osteosarcoma
-
Advaxis Presents New Long-Term Survival Data Greater Than 24-Months at ASCO Annual Meeting
-
Advaxis Selects inVentiv Health Clinical to Conduct Clinical Trials of Immunotherapy Candidates
-
Advaxis's HER2 Immunotherapy Candidate Receives Orphan Drug Designation for Treatment of Osteosarcoma
-
Advaxis to Initiate Clinical Development of ADXS-cHER2 Immunotherapy to Treat Pediatric Bone Cancer
-
Advaxis to Present at 2014 American Society of Clinical Oncology Annual Meeting
-
Japan Patent Office Issues Advaxis a Notice of Allowance for Two Patent Applications Covering Its Cancer Immunotherapy Platform Technology
-
Advaxis Receives Notice of Allowance From U.S. Patent and Trademark Office for Three Patent Applications With Multiple Claims Covering Its Cancer Immunotherapy Platform Technology
-
Advaxis Discusses Global Licensing Agreement for Pet Therapeutics on Conference Call
-
Advaxis Receives Patent in Japan for ADXS-HPV for the Treatment of Cervical Cancer
-
Advaxis Cancer Immunotherapy Featured on CNN
-
Advaxis to Participate in Canaccord Genuity Orphan Drug One-on-One Day
-
Advaxis to Present at the Bloomberg 2014 State of Healthcare Summit
-
Advaxis Engages SynCo Bio Partners for Manufacturing of ADXS-HPV, Its Lead Cancer Immunotherapy Program
-
Advaxis Expands Collaboration With GRU Cancer Center at Georgia Regents University to Conduct Four Cancer Immunotherapy Clinical Trials

